Table 1 Characteristics of the studies included for meta-analysis
Author and year | Country | Population | Study age-group(years) | Sex ratio Male/ Female | Study type | Sample size | Unsuccessful Outcomes (DM+) | Unsuccessful Outcomes (DM-) | Successful Outcomes (DM+) | Successful Outcome (DM-) | The type of DR-TB | The type of DM | Score of quality assessment | Odds ratio (95%Confidence Interval) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
July Mary Johnson (2022) | India (Asian) | In-patients and out-patients | > 18 | 330/132 | Case-control study | 462 | 93 | 336 | 5 | 28 | DR-TB | DM | 7 | 1.5(0.58,4.13) |
Daniel Bekele Ketema (2019) | Ethiopia (Africa) | In-patients and out-patients | All | 283/225 | Cohort study | 508 | 7 | 79 | 9 | 413 | DR-TB | DM | 6 | 4.07(1.47,11.24) |
A. Latif (2018) | Pakistan (Asian) | Community population | ≥ 15 | 2970/2841 | Cross-sectional study | 5811 | 171 | 1631 | 338 | 3671 | DR-TB | Type 2 DM | 9 | 1.14(0.94,1.38) |
Li Shi (2021) | China (Asian) | Hospital patients | ≥ 18 | 196/18 | Case-control study | 214 | 10 | 7 | 97 | 100 | MDR-TB | Type 2 DM | 7 | 1.47(0.54,4.03) |
Khasan Safaev (2021) | Uzbekistan (Asian) | Community population | All | 412/133 | Cohort study | 545 | 13 | 229 | 7 | 296 | MDR-TB | DM | 7 | 2.40(0.94,6.11) |
Subhakar Kandi (2021) | India (Asian) | In-patients and out-patients | All | 201/176 | Case-control study | 377 | 11 | 151 | 20 | 195 | MDR-TB | DM | 5 | 0.71(0.33,1.53) |
Wang Jianjie (2019)* | China (Asian) | In-patients and out-patients | All | 137/415 | Cohort study | 552 | 60 | 97 | 89 | 306 | MDR-TB | DM | 6 | 2.13(1.43,3.17) |
A K JanmeJa (2018) | India (Asian) | Community population | 12–71 | 154/77 | Case-control study | 231 | 17 | 92 | 9 | 113 | MDR-TB | DM | 6 | 2.32(0.99,5.45) |
Tariq Mahmood (2018) | India (Asian) | Hospital patients | > 20 | 106/35 | Cross-sectional study | 141 | 9 | 71 | 4 | 57 | MDR-TB | DM | 6 | 1.81(0.53,6.17) |
Muñoz-Torrico (2017) | Mexico (America) | In-patients | NM | NM | Case-control study | 77 | 25 | 15 | 18 | 19 | MDR-TB | DM | 5 | 1.76(0.71,4.36) |
Baodong Yuan (2017) | China (Asian) | Hospital patients | ≥ 18 | 245/105 | Case-control study | 359 | 32 | 59 | 42 | 226 | MDR-TB | Type 2 DM | 7 | 2.92(1.70,5.02) |
Mohsen A. Gadallah (2015) | Egypt (Africa) | In-patients | 7–76 | 161/67 | Cohort study | 228 | 17 | 53 | 19 | 139 | MDR-TB | DM | 6 | 2.35(1.13,4.85) |
N. Kwak(2015) | Korea (Asian) | Hospital patients | NM | 69/54 | Case-control study | 123 | 0 | 20 | 10 | 93 | MDR-TB | DM | 7 | 0.22(0.01,3.86) |
J.Peter Cegielsk (2015) | Estonia, Latvia, Philippines, Peru, Russia, South Africa, Korea, Taiwan and Thailand (Europe, Asian and African) | Community population | ≥ 18 | 609/364 | Cohort study | 973 | 25 | 226 | 107 | 615 | MDR-TB | DM | 6 | 0.64(0.40,1.01) |
Matthew J. Magee (2014) | Georgia (Asian) | Community population | ≥18 | 1153/268 | Cohort study | 1421 | 36 | 666 | 36 | 683 | MDR-TB | DM | 6 | 1.03(0.64,1.65) |
Young Ae Kang (2013) | Korea (Asian) | Hospital patients | 13–89 | 1039/368 | Case-control study | 1407 | 153 | 617 | 86 | 551 | MDR-TB | DM | 7 | 1.59(1.19,2.12) |
Ma Tarcela Gler (2013) | Philippines (Asian) | Hospital patients | ≥ 18 | 271/168 | Cohort study | 439 | 34 | 95 | 83 | 227 | MDR-TB | DM | 6 | 0.98(0.61,1.56) |
L F Anderson (2013) | England, Wales and Northern Ireland(Europe) | Hospital patients | All | NM | Cohort study | 191 | 6 | 41 | 4 | 140 | MDR-TB | DM | 6 | 5.12(1.38,19.02) |
Shenjie Tang (2013) | China (Asian) | In-patients and out-patients | 14 ~ 88 | 395/191 | Case-control study | 586 | 65 | 281 | 15 | 225 | MDR-TB | DM | 6 | 3.47(1.93,6.25) |
Ekaterina V. Kurbatova (2012) | Russia, Latvia, Estonia, Peru and Philippines (Europe and Asian) | Out-patients | All | NM | Case- control study | 1401 | 23 | 395 | 45 | 938 | MDR-TB | DM | 7 | 1.21(0.72,2.03) |
Medea Gegia (2012) | Georgian (Asian) | the National TB Reference Laboratory | 16–81 | 271/109 | Cohort study | 380 | 16 | 163 | 19 | 182 | MDR-TB | DM | 6 | 0.94(0.47,1.89) |
D.Bendayan (2010)* | Israel (Asian) | In-patients and out-patients | 16–93 | 102/30 | Case- control study | 132 | 6 | 34 | 11 | 81 | MDR-TB | DM | 7 | 1.3(0.44,3.80) |
D.S.Jeon (2008) | Korea (Asian) | Hospital patients | All | NM | Case- control study | 142 | 17 | 97 | 3 | 25 | MDR-TB | DM | 7 | 1.46(0.40,5.38) |
T Yoshiyama (2005) | Japan (Asian) | In-patients and out-patients | All | NM | Case-control study | 74 | 7 | 5 | 14 | 48 | MDR-TB | DM | 6 | 4.80(1.32,17.49) |
Vaira Leimane (2005) | Latvia (Europe) | Hospital Patients, prisoners patients, Community population | 17–78 | NM | Case-control study | 131 | 3 | 21 | 6 | 101 | MDR-TB | DM | 7 | 2.40(0.56,10.39) |